A Comparison of Fosaprepitant and Ondansetron for Preventing Postoperative Nausea and Vomiting in Moderate to High Risk Patients: A Retrospective Database Analysis

Chiaki Murakami, Nami Kakuta, Katsuyoshi Kume, Yoko Sakai, Asuka Kasai, Takuro Oyama, Katsuya Tanaka, Yasuo M Tsutsumi, Chiaki Murakami, Nami Kakuta, Katsuyoshi Kume, Yoko Sakai, Asuka Kasai, Takuro Oyama, Katsuya Tanaka, Yasuo M Tsutsumi

Abstract

Postoperative nausea and vomiting (PONV) occur in 30-50% of patients undergoing general anesthesia and in 70-80% of high PONV risk patients. In this study, we investigated the efficacy of fosaprepitant, a neurokinin-1 (NK1) receptor antagonist, compared to ondansetron, a selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist, in moderate to high PONV risk patients from our previous randomized controlled trials. Patients (171 patients from 4 pooled studies) with the Apfel simplified score ≥ 2 and undergoing general anesthesia were randomly allocated to receive intravenous fosaprepitant 150 mg (NK1 group, n = 82) and intravenous ondansetron 4 mg (ONS group, n = 89) before induction of anesthesia. Incidence of vomiting was significantly lower in the NK1 group compared to the ONS group 0-2, 0-24, and 0-48 hours after surgery (2 versus 17%, 2 versus 28%, and 2 versus 29%, resp.). However, no significant differences in PONV, complete response, rescue antiemetic use, and nausea score were observed between groups 0-48 hours after surgery. In moderate to high PONV risk patients, fosaprepitant decreased the incidence of vomiting and was superior to ondansetron in preventing postoperative vomiting 0-48 hours after surgery.

References

    1. Koivuranta M., Läärä E., Snåre L., Alahuhta S. A survey of postoperative nausea and vomiting. Anaesthesia. 1997;52(5):443–449. doi: 10.1111/j.1365-2044.1997.117-az0113.x.
    1. Apfel C. C., Läärä E., Koivuranta M., Greim C., Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999;91(3):693–700. doi: 10.1097/00000542-199909000-00022.
    1. Sinclair D. R., Chung F., Mezei G. Can postoperative nausea and vomiting be predicted? Anesthesiology. 1999;91(1):109–118. doi: 10.1097/00000542-199907000-00018.
    1. Gan T. J., Diemunsch P., Habib A. S., et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesthesia & Analgesia. 2014;118(1):85–113.
    1. Rust M., Cohen L. A. Single oral dose ondansetron in the prevention of postoperative nausea and emesis. Anaesthesia. 1994;49:16–23. doi: 10.1111/j.1365-2044.1994.tb03578.x.
    1. Gan T. J., Ginsberg B., Grant A. P., Glass P. S. A. Double-blind, randomized comparison of ondansetron and intraoperative propofol to prevent postoperative nausea and vomiting. Anesthesiology. 1996;85(5):1036–1042. doi: 10.1097/00000542-199611000-00011.
    1. Adam F., Chauvin M., Du Manoir B., Langlois M., Sessler D. I., Fletcher D. Small-dose ketamine infusion improves postoperative analgesia and rehabilitation after total knee arthroplasty. Anesthesia & Analgesia. 2005;100(2):475–480. doi: 10.1213/01.ANE.0000142117.82241.DC.
    1. Dorr L. D., Chao L. The emotional state of the patient after total hip and knee arthroplasty. Clinical Orthopaedics and Related Research. 2007;(463):7–12. doi: 10.1097/BLO.0b013e318149296c.
    1. Backes J. R., Bentley J. C., Politi J. R., Chambers B. T. Dexamethasone reduces length of hospitalization and improves postoperative pain and nausea after total joint arthroplasty: a prospective, randomized controlled trial. The Journal of Arthroplasty. 2013;28(8):11–17. doi: 10.1016/j.arth.2013.05.041.
    1. Lasseter K. C., Gambale J., Pharm D., et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. Clinical Pharmacology and Therapeutics. 2007;47(7):834–840. doi: 10.1177/0091270007301800.
    1. Gan T. J., Apfel C. C., Kovac A., et al. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesthesia & Analgesia. 2007;104(5):1082–1089. doi: 10.1213/01.ane.0000263277.35140.a3.
    1. Diemunsch P., Gan T. J., Philip B. K., et al. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind Phase III trial in patients undergoing open abdominal surgery. British Journal of Anaesthesia. 2007;99(2):202–211. doi: 10.1093/bja/aem133.
    1. Diemunsch P., Apfel C., Gan T. J., et al. Preventing postoperative nausea and vomiting: Post hoc analysis of pooled data from two randomized active-controlled trials of aprepitant. Current Medical Research and Opinion. 2007;23(10):2559–2565. doi: 10.1185/030079907X233115.
    1. Langford P., Chrisp P. Fosaprepitant and aprepitant: An update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting. Core Evidence. 2010;5:77–90. doi: 10.2147/CE.S6012.
    1. Tsutsumi Y. M., Kakuta N., Soga T., et al. The Effects of intravenous fosaprepitant and ondansetron for the prevention of postoperative nausea and vomiting in neurosurgery patients: A prospective, randomized, double-blinded study. BioMed Research International. 2014;2014 doi: 10.1155/2014/307025.307025
    1. Soga T., Kume K., Kakuta N., et al. Fosaprepitant versus ondansetron for the prevention of postoperative nausea and vomiting in patients who undergo gynecologic abdominal surgery with patient-controlled epidural analgesia: a prospective, randomized, double-blind study. Journal of Anesthesia & Clinical Research. 2015;29(5):696–701. doi: 10.1007/s00540-015-2006-z.
    1. Kakuta N., Kume K., Hamaguchi E., et al. The effects of intravenous fosaprepitant and ondansetron in the prevention of postoperative nausea and vomiting in patients who underwent lower limb surgery: a prospective, randomized, double-blind study. Journal of Anesthesia & Clinical Research. 2015;29(6):836–841. doi: 10.1007/s00540-015-2054-4.
    1. Diemunsch P., Joshi G. P., Brichant J.-F. Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting. British Journal of Anaesthesia. 2009;103(1):7–13. doi: 10.1093/bja/aep125.
    1. Aapro M., Carides A., Rapoport B. L., Schmoll H.-J., Zhang L., Warr D. Aprepitant and fosaprepitant: A 10-year review of efficacy and safety. The Oncologist. 2015;20(4):450–458. doi: 10.1634/theoncologist.2014-0229.
    1. Einhorn L. H., Rapoport B., Navari R. M., Herrstedt J., Brames M. J. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Supportive Care in Cancer. 2017;25(1):303–308. doi: 10.1007/s00520-016-3449-y.
    1. Grunberg S., Chua D., Maru A., et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: Randomized, double-blind study protocol-EASE. Journal of Clinical Oncology. 2011;29(11):1495–1501. doi: 10.1200/JCO.2010.31.7859.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa